These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 8446773)
21. A monoclonal antibody directed to sulfatide inhibits the binding of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein to macrophages but not their infection by the virus. Seddiki N; Ramdani A; Saffar L; Portoukalian J; Gluckman JC; Gattegno L Biochim Biophys Acta; 1994 Feb; 1225(3):289-96. PubMed ID: 8312376 [TBL] [Abstract][Full Text] [Related]
22. PCR analysis of HIV1 infection of macrophages: virus entry is CD4-dependent. Collin M; Herbein G; Montaner L; Gordon S Res Virol; 1993; 144(1):13-9. PubMed ID: 8446772 [TBL] [Abstract][Full Text] [Related]
23. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. Abacioglu YH; Fouts TR; Laman JD; Claassen E; Pincus SH; Moore JP; Roby CA; Kamin-Lewis R; Lewis GK AIDS Res Hum Retroviruses; 1994 Apr; 10(4):371-81. PubMed ID: 8068416 [TBL] [Abstract][Full Text] [Related]
24. CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop. Ratto S; Sitz KV; Scherer AM; Loomis LD; Cox JH; Redfield RR; Birx DL J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):128-36. PubMed ID: 8556394 [TBL] [Abstract][Full Text] [Related]
25. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds. Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646 [TBL] [Abstract][Full Text] [Related]
26. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors. Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996 [TBL] [Abstract][Full Text] [Related]
27. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. Srivastava IK; Stamatatos L; Kan E; Vajdy M; Lian Y; Hilt S; Martin L; Vita C; Zhu P; Roux KH; Vojtech L; C Montefiori D; Donnelly J; Ulmer JB; Barnett SW J Virol; 2003 Oct; 77(20):11244-59. PubMed ID: 14512572 [TBL] [Abstract][Full Text] [Related]
28. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. Stamatatos L; Lim M; Cheng-Mayer C AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360 [TBL] [Abstract][Full Text] [Related]
29. The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated. Yang C; Spies CP; Compans RW Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9871-5. PubMed ID: 7568235 [TBL] [Abstract][Full Text] [Related]
30. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein. Benjouad A; Mabrouk K; Gluckman JC; Fenouillet E FEBS Lett; 1994 Mar; 341(2-3):244-50. PubMed ID: 8137947 [TBL] [Abstract][Full Text] [Related]
31. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694 [TBL] [Abstract][Full Text] [Related]
32. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins. Neurath AR; Strick N; Li YY; Jiang S AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138 [TBL] [Abstract][Full Text] [Related]
33. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120. Keller PW; Morrison O; Vassell R; Weiss CD J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245 [TBL] [Abstract][Full Text] [Related]
34. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Wild C; Oas T; McDanal C; Bolognesi D; Matthews T Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10537-41. PubMed ID: 1438243 [TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein. Zaghouani H; Hall B; Shah H; Bona C Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238 [No Abstract] [Full Text] [Related]
36. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. Yuan W; Craig S; Si Z; Farzan M; Sodroski J J Virol; 2004 May; 78(10):5448-57. PubMed ID: 15113923 [TBL] [Abstract][Full Text] [Related]
38. HIV-1 gp41 contains two sites for interaction with several proteins on the helper T-lymphoid cell line, H9. Chen YH; Ebenbichler C; Vornhagen R; Schulz TF; Steindl F; Böck G; Katinger H; Dierich MP AIDS; 1992 Jun; 6(6):533-9. PubMed ID: 1388873 [TBL] [Abstract][Full Text] [Related]
39. The envelope of HIV-1 as a key component to infectivity. Buchbinder A Prog AIDS Pathol; 1990; 2():1-11. PubMed ID: 2103853 [No Abstract] [Full Text] [Related]
40. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]